BioSpace News Archive

Foundation also announces three Global Goals award winners and launches two innovative partnerships to address COVID-19 impacts in Kenya

Growing instances of hearing issues among older population is working as a driving factor for the growth of the global bone conduction hearing devices market.

eClinical solutions have gathered substantial market proposition among biopharma and pharma companies for streamlining their clinical trials and insights discovery across various phases from I to IV.

Obesity has reached concerning levels around the world, with an increasing number of people tipping the scales.

Rehabilitation is the process of bringing back from dysfunction to appropriate function. Loss of function can be isolated for a part of the body or multiple functional parts, which require multi directional therapy.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced the appointment of Michael Arciero as Vice-President of Intellectual Property and Commercial Development.

Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAs

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for

Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T. A webcast of the presentation will be available under the “Investors and Media” section of Seres’ website and will be archived for 21 days. About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCR

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food and Drug Administration has granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.